​

Merck (MRK) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MRK Stock Forecast

Merck stock forecast is as follows: an average price target of $135.83 (represents a 38.21% upside from MRK’s last price of $98.28) and a rating consensus of 'Buy', based on 24 wall street analysts offering a 1-year stock forecast.

MRK Price Target

The average price target for Merck (MRK) is $135.83 based on 1-year price targets from 24 Wall Street analysts in the past 3 months, with a price target range of $148.00 to $110.00. This represents a potential 38.21% upside from MRK's last price of $98.28.

MRK Analyst Ratings

Buy

According to 24 Wall Street analysts, Merck's rating consensus is 'Buy'. The analyst rating breakdown for MRK stock is 0 'Strong Buy' (0.00%), 22 'Buy' (91.67%), 2 'Hold' (8.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Merck Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 02, 2024Courtney BreenBernstein$110.00$100.699.25%11.93%
Nov 15, 2024Akash TewariJefferies$148.00$98.3650.47%50.59%
Nov 01, 2024Evan David SeigermanBMO Capital$136.00$101.8833.49%38.38%
Oct 09, 2024Trung HuynhUBS$136.00$108.8824.91%38.38%
Oct 07, 2024Carter GouldBarclays$140.00$109.7727.54%42.45%
Aug 15, 2024Akash TewariJefferies$147.00$113.4929.53%49.57%
Jul 31, 2024Colin BristowUBS$142.00$112.8925.79%44.49%
Jul 31, 2024Geoff MeachamBank of America Securities$145.00$115.2125.86%47.54%
Jun 12, 2024Mohit BansalWells Fargo$140.00$131.056.83%42.45%
May 30, 2024Evan David SeigermanBMO Capital$148.00$127.7115.89%50.59%
Mar 27, 2024Truist Financial$142.00$130.818.55%44.49%
Mar 27, 2024Akash TewariJefferies$145.00$130.1811.38%47.54%
Mar 27, 2024Mohit BansalWells Fargo$135.00$130.193.69%37.36%
Nov 22, 2023Evan David SeigermanLoop Capital Markets$132.00$101.4430.13%34.31%
Apr 12, 2023Jay OlsonOppenheimer$147.00$56.34160.92%49.57%
Feb 03, 2023Wells Fargo$120.00$103.2816.19%22.10%
Feb 03, 2023Morgan Stanley$99.00$103.46-4.31%0.73%
Jan 03, 2023Wells Fargo$125.00$110.6113.00%27.19%
Dec 19, 2022Cantor Fitzgerald$135.00$109.2023.63%37.36%
Nov 18, 2022Credit Suisse$120.00$102.3117.29%22.10%
Sep 30, 2022Leerink Partners$110.00$86.6426.96%11.93%
Sep 12, 2022Leerink Partners$109.00$87.3424.80%10.91%
Jul 29, 2022Barclays$101.00$88.6313.96%2.77%
Jul 29, 2022Morgan Stanley$92.00$89.263.07%-6.39%
Jul 29, 2022Leerink Partners$105.00$89.9416.74%6.84%
Jul 18, 2022UBS$98.00$94.343.87%-0.28%
Jul 13, 2022Atlantic Equities$110.00$93.6017.52%11.93%
Jul 08, 2022Morgan Stanley$88.00$93.01-5.39%-10.46%
Apr 29, 2022Morgan Stanley$87.00$88.61-1.82%-11.48%
Apr 29, 2022Leerink Partners$102.00$88.5815.15%3.79%
Apr 21, 2022Leerink Partners$97.00$86.4612.19%-1.30%
Apr 16, 2022Carter GouldBarclays$97.00$86.9111.61%-1.30%
Apr 11, 2022Terence FlynnMorgan Stanley$80.00$86.63-7.65%-18.60%
Apr 10, 2022Evan David SeigermanBMO Capital$87.00$87.68-0.78%-11.48%
Dec 17, 2021Chris ShibutaniGoldman Sachs$93.00$75.0223.97%-5.37%
Dec 13, 2021Colin BristowUBS$76.00$72.095.42%-22.67%
Nov 29, 2021Andrew BaumCitigroup$85.00$73.5315.60%-13.51%
Nov 01, 2021Carter GouldBarclays$94.00$86.258.99%-4.35%
Nov 01, 2021David ToungArgus Research$110.00$86.2527.54%11.93%
Oct 29, 2021Geoff MeachamBank of America Securities$86.00$86.45-0.52%-12.49%
Oct 29, 2021Tim AndersonWolfe Research$94.00$86.458.73%-4.35%
Jul 29, 2021Daniel BusbyRBC Capital$80.00$74.866.87%-18.60%

The latest Merck stock forecast, released on Dec 02, 2024 by Courtney Breen from Bernstein, set a price target of $110.00, which represents a 9.25% increase from the stock price at the time of the forecast ($100.69), and a 11.93% increase from MRK last price ($98.28).

Merck Price Target by Period

1M3M12M
# Anlaysts-313
Avg Price Target-$131.33$139.54
Last Closing Price$98.28$98.28$98.28
Upside/Downside-100.00%33.63%41.98%

In the current month, the average price target of Merck stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Merck's last price of $98.28. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Dec 02, 2024BernsteinMarket PerformMarket PerformHold
Nov 15, 2024JefferiesBuyBuyHold
Nov 01, 2024Leerink PartnersOutperformOutperformHold
Oct 17, 2024BernsteinMarket PerformInitialise
Oct 09, 2024UBSBuyBuyHold
Oct 07, 2024BarclaysOverweightOverweightHold
Sep 16, 2024Wells FargoBuyBuyHold
Sep 16, 2024UBSUnderperformUnderperformHold
Sep 13, 2024NeedhamHoldHoldHold
Sep 03, 2024Cowen & Co.BuyBuyHold
Aug 15, 2024JefferiesBuyBuyHold
Aug 05, 2024Goldman SachsBuyBuyHold
Jul 31, 2024UBSBuyBuyHold
Jul 31, 2024Wells FargoEqual-WeightEqual-WeightHold
Jul 11, 2024Morgan StanleyBuyBuyHold
Jul 11, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Jun 18, 2024Truist FinancialUnderperformUnderperformHold
Jun 18, 2024Wells FargoBuyBuyHold
Jun 12, 2024Wells FargoEqual-WeightEqual-WeightHold
May 30, 2024BMO CapitalOutperformOutperformHold
Apr 01, 2024UBSUnderperformUnderperformHold
Apr 01, 2024Wells FargoBuyBuyHold
Mar 27, 2024Cantor FitzgeraldOverweightOverweightHold
Mar 27, 2024JefferiesBuyBuyHold
Feb 29, 2024Wells FargoBuyBuyHold
Feb 02, 2024Deutsche BankBuyBuyHold
Feb 02, 2024Cowen & Co.UnderperformUnderperformHold
Jan 09, 2024Deutsche BankUnderperformUnderperformHold
Jan 09, 2024Morgan StanleyBuyBuyHold
Nov 22, 2023BMO CapitalOutperformOutperformHold
Oct 27, 2023BMO CapitalOutperformUpgrade
Apr 12, 2023OppenheimerOutperformOutperformHold
Mar 10, 2023CitigroupBuyBuyHold
Mar 07, 2023Atlantic EquitiesOverweightOverweightHold
Feb 22, 2023CitigroupBuyUpgrade
Feb 22, 2023Wolfe ResearchOutperformUpgrade
Feb 03, 2023Wells FargoOverweightOverweightHold
Feb 03, 2023SVB LeerinkOutperformOutperformHold
Jan 04, 2023Morgan StanleyBuyOverweightUpgrade
Jan 04, 2023Bank of America SecuritiesNeutralBuyUpgrade
Jan 03, 2023Wells FargoOverweightOverweightHold
Dec 19, 2022Cantor FitzgeraldOverweightOverweightHold
Nov 18, 2022Credit SuisseOutperformInitialise
Oct 11, 2022Atlantic EquitiesOverweightOverweightHold
Oct 10, 2022Prescience PointBuyUpgrade
Oct 10, 2022Bank of America SecuritiesNeutralUpgrade
Oct 10, 2022Morgan StanleyBuyBuyHold
Oct 10, 2022GuggenheimBuyUpgrade
Sep 22, 2022UBSNeutralBuyUpgrade
Sep 14, 2022Deutsche BankHoldInitialise
Sep 12, 2022SVB LeerinkOutperformOutperformHold
Jul 29, 2022BarclaysOverweightOverweightHold
Jul 29, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Jul 29, 2022SVB LeerinkOutperformOutperformHold
Jul 28, 2022Mizuho SecuritiesBuyBuyHold
Jul 18, 2022UBSNeutralNeutralHold
Jul 13, 2022Atlantic EquitiesOverweightOverweightHold
Jul 08, 2022Cowen & Co.Market PerformMarket PerformHold
Jul 08, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Jul 06, 2022DaiwaOutperformUpgrade
Apr 29, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Apr 29, 2022Wells FargoOverweightOverweightHold
Apr 29, 2022SVB LeerinkOutperformOutperformHold
Apr 15, 2022BarclaysOverweightOverweightHold
Dec 18, 2021Goldman SachsBuyInitialise
Dec 12, 2021Wells FargoOverweightInitialise

Merck's last stock rating was published by Bernstein on Dec 02, 2024. The company gave MRK a "Market Perform" rating, the same as its previous rate.

Merck Financial Forecast

Merck Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$15.96B$15.04B$14.49B$13.83B$14.96B$14.59B$15.90B$13.52B$13.15B$11.40B$12.08B$12.52B$12.55B$10.87B$12.06B$11.87B$12.40B
Avg Forecast$17.46B$18.35B$17.45B$17.33B$16.64B$17.39B$16.78B$16.28B$15.49B$16.47B$15.87B$15.21B$14.49B$15.30B$14.44B$13.79B$13.66B$14.07B$13.86B$14.56B$13.16B$12.32B$11.23B$12.61B$12.67B$12.21B$10.40B$11.48B$11.98B$11.64B
High Forecast$18.11B$19.03B$18.10B$17.98B$17.26B$18.04B$17.41B$16.80B$15.74B$16.50B$15.87B$15.21B$14.88B$15.57B$14.98B$14.31B$13.98B$14.07B$13.86B$14.56B$13.16B$12.32B$11.23B$12.61B$12.67B$12.21B$10.40B$11.48B$11.98B$11.64B
Low Forecast$16.95B$17.81B$16.94B$16.83B$16.16B$16.88B$16.29B$15.95B$15.36B$16.44B$15.87B$15.21B$14.26B$14.60B$14.02B$13.39B$13.38B$14.07B$13.86B$14.56B$13.16B$12.32B$11.23B$12.61B$12.67B$12.21B$10.40B$11.48B$11.98B$11.64B
# Analysts22221114943471599131313137777916811711
Surprise %-------------1.04%1.04%1.05%1.01%1.06%1.05%1.09%1.03%1.07%1.02%0.96%0.99%1.03%1.05%1.05%0.99%1.07%

Merck's average Quarter revenue forecast for Dec 23 based on 7 analysts is $14.49B, with a low forecast of $14.26B, and a high forecast of $14.88B. MRK's average Quarter revenue forecast represents a -9.23% decrease compared to the company's last Quarter revenue of $15.96B (Sep 23).

Merck EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts22221114943471599131313137777916811711
EBITDA-------------$6.00B$-4.86B$3.87B$3.54B$4.20B$5.21B$5.67B$4.89B$6.22B$2.94B$4.58B$-885.00M$4.48B$4.77B$4.87B$3.94B$3.42B
Avg Forecast$4.99B$5.24B$4.99B$4.95B$4.76B$4.97B$4.80B$4.65B$4.43B$4.71B$4.54B$6.26B$4.14B$4.37B$4.13B$5.69B$4.43B$3.86B$3.80B$5.17B$3.61B$3.38B$3.08B$5.23B$3.47B$3.35B$2.85B$4.29B$3.28B$3.19B
High Forecast$5.17B$5.44B$5.17B$5.14B$4.93B$5.16B$4.97B$4.80B$4.50B$4.72B$4.54B$7.51B$4.25B$4.45B$4.28B$6.83B$5.31B$3.86B$3.80B$6.21B$3.61B$3.38B$3.08B$6.28B$3.47B$3.35B$2.85B$5.15B$3.28B$3.19B
Low Forecast$4.84B$5.09B$4.84B$4.81B$4.62B$4.83B$4.66B$4.56B$4.39B$4.70B$4.54B$5.01B$4.08B$4.17B$4.01B$4.55B$3.54B$3.86B$3.80B$4.14B$3.61B$3.38B$3.08B$4.19B$3.47B$3.35B$2.85B$3.43B$3.28B$3.19B
Surprise %-------------1.37%-1.18%0.68%0.80%1.09%1.37%1.10%1.35%1.84%0.95%0.88%-0.25%1.34%1.67%1.14%1.20%1.07%

7 analysts predict MRK's average Quarter EBITDA for Dec 23 to be $4.14B, with a high of $4.25B and a low of $4.08B. This is -30.96% lower than Merck's previous annual EBITDA (Sep 23) of $6.00B.

Merck Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts22221114943471599131313137777916811711
Net Income-------------$4.75B$-5.97B$2.82B$3.02B$3.25B$3.94B$4.31B$3.82B$4.57B$1.54B$3.18B$-2.09B$2.94B$3.00B$3.22B$2.36B$1.90B
Avg Forecast$5.51B$6.61B$6.30B$6.38B$5.30B$6.01B$5.72B$5.55B$4.59B$3.77B$5.51B$4.33B$-275.62M$4.96B$-5.54B$3.94B$3.40B$4.34B$4.33B$3.58B$3.88B$3.93B$3.33B$3.63B$3.36B$3.49B$2.57B$2.83B$2.79B$3.01B
High Forecast$5.78B$6.93B$6.61B$6.69B$5.55B$6.30B$6.00B$5.80B$4.94B$3.84B$5.51B$5.20B$-61.25M$5.29B$-5.33B$4.73B$4.09B$4.34B$4.33B$4.30B$3.88B$3.93B$3.33B$4.35B$3.36B$3.49B$2.57B$3.40B$2.79B$3.01B
Low Forecast$5.30B$6.36B$6.06B$6.14B$5.10B$5.78B$5.50B$4.88B$4.34B$3.70B$5.50B$3.47B$-428.74M$4.56B$-5.81B$3.15B$2.72B$4.34B$4.33B$2.86B$3.88B$3.93B$3.33B$2.90B$3.36B$3.49B$2.57B$2.27B$2.79B$3.01B
Surprise %-------------0.96%1.08%0.72%0.89%0.75%0.91%1.20%0.98%1.16%0.46%0.88%-0.62%0.84%1.17%1.14%0.85%0.63%

Merck's average Quarter net income forecast for Dec 23 is $-275.62M, with a range of $-428.74M to $-61.25M. MRK's average Quarter net income forecast represents a -105.81% decrease compared to the company's last Quarter net income of $4.75B (Sep 23).

Merck SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts22221114943471599131313137777916811711
SG&A-------------$2.52B$2.70B$2.48B$2.69B$2.52B$2.51B$2.32B$2.83B$2.34B$2.28B$2.63B$3.08B$2.45B$2.38B$2.56B$2.89B$2.59B
Avg Forecast$3.44B$3.61B$3.43B$3.41B$3.28B$3.42B$3.30B$3.20B$3.05B$3.24B$3.12B$2.33B$2.85B$3.01B$2.84B$2.12B$2.56B$2.77B$2.73B$1.93B$2.59B$2.42B$2.21B$3.00B$2.49B$2.40B$2.05B$2.25B$2.36B$2.29B
High Forecast$3.56B$3.75B$3.56B$3.54B$3.40B$3.55B$3.43B$3.31B$3.10B$3.25B$3.12B$2.80B$2.93B$3.06B$2.95B$2.55B$3.08B$2.77B$2.73B$2.32B$2.59B$2.42B$2.21B$3.61B$2.49B$2.40B$2.05B$2.70B$2.36B$2.29B
Low Forecast$3.34B$3.51B$3.33B$3.31B$3.18B$3.32B$3.21B$3.14B$3.02B$3.24B$3.12B$1.87B$2.81B$2.87B$2.76B$1.70B$2.05B$2.77B$2.73B$1.54B$2.59B$2.42B$2.21B$2.40B$2.49B$2.40B$2.05B$1.80B$2.36B$2.29B
Surprise %-------------0.84%0.95%1.17%1.05%0.91%0.92%1.20%1.09%0.96%1.03%0.88%1.24%1.02%1.16%1.14%1.23%1.13%

Merck's average Quarter SG&A projection for Dec 23 is $2.85B, based on 7 Wall Street analysts, with a range of $2.81B to $2.93B. The forecast indicates a 13.22% rise compared to MRK last annual SG&A of $2.52B (Sep 23).

Merck EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts22221114943471599131313137777916811711
EPS-------------$1.87$-2.35$1.11$1.19$1.28$1.56$1.70$1.51$1.81$0.61$1.26$-0.83$1.16$1.19$1.28$0.93$0.75
Avg Forecast$2.17$2.60$2.48$2.51$2.08$2.37$2.25$2.18$1.81$1.48$2.17$1.89$-0.11$1.95$-2.18$1.32$1.53$1.71$1.70$1.83$1.53$1.55$1.31$1.53$1.32$1.37$1.01$1.28$1.10$1.18
High Forecast$2.27$2.73$2.60$2.63$2.19$2.48$2.36$2.28$1.94$1.51$2.17$1.89$-0.02$2.08$-2.10$1.38$1.58$1.71$1.70$1.83$1.53$1.55$1.31$1.53$1.32$1.37$1.01$1.28$1.10$1.18
Low Forecast$2.09$2.50$2.39$2.41$2.01$2.28$2.17$1.92$1.71$1.46$2.17$1.88$-0.17$1.79$-2.29$1.27$1.49$1.71$1.70$1.83$1.53$1.55$1.31$1.53$1.32$1.37$1.01$1.28$1.10$1.18
Surprise %-------------0.96%1.08%0.84%0.78%0.75%0.92%0.93%0.99%1.17%0.47%0.82%-0.63%0.85%1.18%1.00%0.85%0.63%

According to 7 Wall Street analysts, Merck's projected average Quarter EPS for Dec 23 is $-0.11, with a low estimate of $-0.17 and a high estimate of $-0.02. This represents a -105.80% decrease compared to MRK previous annual EPS of $1.87 (Sep 23).

Merck Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
MRKMerck$98.28$135.8338.21%Buy
LLYEli Lilly and$804.08$1.01K26.12%Buy
PFEPfizer$26.62$32.1720.85%Hold
ABBVAbbVie$175.26$211.2020.51%Buy
AMGNAmgen$281.68$338.2220.07%Buy
JNJJohnson & Johnson$151.15$178.7118.23%Buy
BMYBristol-Myers Squibb$59.05$61.003.30%Hold
GILDGilead Sciences$95.59$88.88-7.02%Buy

MRK Forecast FAQ

Is Merck a good buy?

Yes, according to 24 Wall Street analysts, Merck (MRK) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 22 'Buy' recommendations, accounting for 91.67% of MRK's total ratings.

What is MRK's price target?

Merck (MRK) average price target is $135.83 with a range of $110 to $148, implying a 38.21% from its last price of $98.28. The data is based on 24 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Merck stock go up soon?

According to Wall Street analysts' prediction for MRK stock, the company can go up by 38.21% (from the last price of $98.28 to the average price target of $135.83), up by 50.59% based on the highest stock price target, and up by 11.93% based on the lowest stock price target.

Can Merck stock reach $150?

MRK's average twelve months analyst stock price target of $135.83 does not support the claim that Merck can reach $150 in the near future.

What are Merck's analysts' financial forecasts?

Merck's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $67.1B (high $69.51B, low $65.28B), average EBITDA is $19.17B (high $19.87B, low $18.66B), average net income is $22.57B (high $23.65B, low $21.26B), average SG&A $13.21B (high $13.68B, low $12.85B), and average EPS is $8.88 (high $9.31, low $8.37). MRK's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $70.58B (high $73.21B, low $68.52B), average EBITDA is $20.17B (high $20.92B, low $19.58B), average net income is $24.8B (high $26B, low $23.86B), average SG&A $13.89B (high $14.41B, low $13.49B), and average EPS is $9.76 (high $10.23, low $9.39).

Did the MRK's actual financial results beat the analysts' financial forecasts?

Based on Merck's last annual report (Dec 2022), the company's revenue was $59.28B, beating the average analysts forecast of $56.13B by 5.61%. Apple's EBITDA was $18.62B, beating the average prediction of $17.26B by 7.90%. The company's net income was $14.52B, missing the average estimation of $15.66B by -7.27%. Apple's SG&A was $10.04B, beating the average forecast of $9.99B by 0.53%. Lastly, the company's EPS was $5.73, missing the average prediction of $6.77 by -15.36%. In terms of the last quarterly report (Sep 2023), Merck's revenue was $15.96B, beating the average analysts' forecast of $15.3B by 4.35%. The company's EBITDA was $6B, beating the average prediction of $4.37B by 37.21%. Merck's net income was $4.74B, missing the average estimation of $4.96B by -4.40%. The company's SG&A was $2.52B, missing the average forecast of $3.01B by -16.34%. Lastly, the company's EPS was $1.87, missing the average prediction of $1.95 by -4.27%